Date: 2015-04-27
Type of information: Product acquisition
Compound: DE-105
Company: R-Tech Ueno (Japan) Santen Pharmaceutical (Japan)
Therapeutic area: Ophtalmological diseases
Type agreement: product acquisition
Action mechanism: peptide. DE-105 is an ophthalmic solution of neurotrophic factor peptide.
Disease: severe persistent corneal epithelial defects
Details: * On April 27, 2015, R-Tech Ueno has acquired the right to develop and commercialize DE-105 from Santen Pharmaceutical. DE-105 is a treatment targeting at persistent corneal epithelial defects that Santen has been developing. By acquisition of this right, R-Tech Ueno undertakes development of this agent towards commercialization going forward. R-Tech Ueno have also concluded an agreement with the inventor of DE-105, Professor Emeritus Teruo Nishida (Graduate School of Medicine, Yamaguchi University) to invite him as medical advisor of R-Tech Ueno. This ophtalmic solution has been developed as a treatment for severe persistent corneal epithelial defects caused by corneal sensory nerve disorder. It is currently at the stage of Phase I clinical trial in the United States and Phase II clinical trial in Japan).The acquisition includes the patents of DE-105 application in the fields of ophthalmology, dermatology, gastrointestinal medicine but also the right of development overseas as well as in Japan.
Financial terms:
Latest news:
